Nyxoah (NASDAQ:NYXH) Trading 1.2% Higher – Here’s What Happened

Nyxoah S.A. (NASDAQ:NYXH)’s share price rose 1.2% on Friday . The company traded as high as $9.16 and last traded at $9.15. Approximately 31,729 shares traded hands during trading, a decline of 53% from the average daily volume of 66,965 shares. The stock had previously closed at $9.04.

Analyst Upgrades and Downgrades

NYXH has been the topic of a number of analyst reports. HC Wainwright reiterated a “buy” rating and issued a $17.00 price target on shares of Nyxoah in a report on Friday, December 13th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $16.00 target price on shares of Nyxoah in a research note on Tuesday, November 5th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $17.00.

Nyxoah Price Performance

The stock has a 50-day moving average price of $8.44 and a two-hundred day moving average price of $8.47. The stock has a market cap of $228.20 million, a price-to-earnings ratio of -4.89 and a beta of 1.35. The company has a current ratio of 5.28, a quick ratio of 4.95 and a debt-to-equity ratio of 0.21.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Nyxoah stock. CVI Holdings LLC acquired a new position in Nyxoah S.A. (NASDAQ:NYXH) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 183,590 shares of the company’s stock, valued at approximately $1,292,000. Nyxoah comprises 1.2% of CVI Holdings LLC’s investment portfolio, making the stock its 13th biggest holding. CVI Holdings LLC owned about 0.74% of Nyxoah as of its most recent SEC filing.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.